Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: VistaGen Therapeutics Inc. VSTA

VistaGen Therapeutics, Inc. (VSTA) is Optimistic About Its Depression Medicine

Depression, as many of us know, is more than just a sad or melancholy mood. It’s more than just having “the blues.” Sometimes it can be a very debilitating condition that can prevent people from having productive lives – and … Continue reading

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment

VistaGen Therapeutics, Inc. (VSTA) – Developing Leading-Edge Biotechnology Offerings

VistaGen Therapeutics is bringing human biology to the front end of the long and costly drug development process. Among the most troubling aspects of drug development are unexpected heart and liver toxicities that often arise during human testing. Applying its … Continue reading

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment

VistaGen Therapeutics, Inc. (VSTA) AV-101 Rivals Ketamine and Other Next-Gen Anti-depressants

On the street ketamine is referred to as “Special K,” a drug popular in the party scene because of its hallucinogenic and other psychotomimetic, or psychosis-like, effects. In the operating room, ketamine has long been used for general anesthesia, and … Continue reading

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment

VistaGen Therapeutics, Inc. (VSTA) Embarking on Key Stage 2 Clinical Trial of Potential Breakthrough Major Depression Therapy

With the very public suicide of actor/comedian Robin Williams recently, the battle with major depressive disorder, or MDD, has moved even more into the public light. VistaGen Therapeutics, Inc. (OTCQB: VSTA) has become one of a small group of companies … Continue reading

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment

VistaGen Therapeutics Inc. (VSTA) AV-101 Poised to Emerge as a Leading Candidate in Multibillion Dollar Global Antidepressant Market

Depression affects nearly 7% of all adults in the U.S. and over 350M people worldwide according to the World Health Organization, and it is a major contributor to overall disease statistics. GBI Research forecasts the global antidepressant market as growing … Continue reading

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment

VistaGen Therapeutics, Inc. (VSTA) Authorizes Letter of Intent with NIMH for NIH-Sponsored Phase 2 Study of AV-101 in Major Depressive Disorder

VistaGen signed a Letter of Intent to enter into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Mental Health (NIMH), part of the National Institutes of Health (NIH), to collaborate on a NIMH-sponsored Phase 2 clinical … Continue reading

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment

VistaGen Therapeutics, Inc. (VSTA) Sees AV-101 as Potential Breakthrough Drug for Major Depressive Disorder

Potential to Address Major U.S. and Global Need It’s one of the single most sought-after drugs in the medical industry, and biotechnology company VistaGen Therapeutics may have it. What is so desperately needed is a drug able to treat a … Continue reading

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment

VistaGen Therapeutics, Inc. (VSTA) Receives Notice of Allowance for Stem Cell Technology

Today before the opening bell, VistaGen Therapeutics announced its reception of a Notice of Allowance from the Canadian Intellectual Property Office. The Notice of Allowance enables further expansion of VistaGen Therapeutics’ intellectual property portfolio, which consists of pluripotent stem cell … Continue reading

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment

VistaGen Therapeutics, Inc. (VSTA) Provides Reverse Stock Split FAQs

Last week, VistaGen Therapeutics implemented a 1-for-20 reverse split of its common stock. As a result, the number of shares of the company’s common stock outstanding was reduced from approximately 25.5 million to approximately 1.2 million. Because the stock price … Continue reading

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment

VistaGen Therapeutics, Inc. (VSTA) Announces New Agreement with Largest Shareholder

In an 8-K filed with the SEC today, VistaGen Therapeutics announced that Platinum Long Term Growth VII, LLC, the company’s largest investor, has entered into an Amended and Restated Note Conversion Agreement and Warrant Amendment. According the SEC filing, Platinum … Continue reading

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment